Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis

Bone Marrow Transplantation

Volumn 22, Issue 6, 1998, Pages 541-545

  Byrne, J L ^a   Stainer, C ^a   Hyde, H ^a   Miflin, G ^a   Haynes, A P ^a   Bessell, E M ^a   Russell, N H ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Bone marrow transplantation; Cyclosporin A; GVHD; Leukaemia

Indexed keywords

CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROBABILITY; RELAPSE; STEM CELL TRANSPLANTATION;

EID: 0031663914     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701396     Document Type: Article

References (15)

1. Storb R, Deeg H, Whitehead J et al. MTX and CsA compared with CsA alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukaemia. New Engl J Med 1986; 314: 729-733.
2. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine vs cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukaemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
3. Ruutu T, Niederweiser D, Gratwohl A, Apperley J. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759-764.
4. Nash R, Sullivan Pepe M, Storb R el al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
5. Bacigalupo A, Van Lint M, Occhini F et al. Increased risk of leukaemia relapse with high-dose cyclosporin A after allo- geneic marrow transplantation for acute leukaemia. Blood 1991; 77: 1423-1428.
6. Hunter A, Bessell E, Russell NH. Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant 1992; 10: 431-434.
7. Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia - results of a randomised multicentre trial. Bone Marrow Transplant 1998 21: 995-1003.
8. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplant 1974; 18: 295-304.
9. Schulman K, Sullivan KM, Weiden P, et al. Chronic graft-versus-host disease in man: a long term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
10. Chao N, Schmidt G, Niland J et al. Cyclosporine, MTX and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. New Engl J Med 1993; 329: 1225-1230.
11. Ringden O, Kersey J. Prevention and therapy of GVHD - full report from a workshop. Bone Marrow Transplant 1992; 10S: 22-24.
12. Ringden O, Horowitz MM, Sendel P et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukaemia? Blood 1993; 81: 1094-1101.
13. Aschan J, Ringden O, Sundverg B et al. Methotrexate combined with cyclosporin A decreases graft-versus-host disease but increases leukaemic relapse compared to monotherapy. Bone Marrow Transplant 1991; 7: 113-119.
14. van Rhee F, Szydlo R, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukaemia in chronic phase: a report from the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-560.
15. Zittoun R, Mandelli F, Willemze R et al. Autologous or allogeneic BMT compared with intensive chemotherapy in acute myeloblastic leukaemia. New Engl J Med 1995; 3324: 217-223.